Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
Dianthus Therapeutics (NASDAQ:DNTH) reported Q2 2025 financial results and business updates, highlighting significant progress in its clinical programs. The company's lead drug candidate claseprubart (DNTH103) is advancing in multiple trials:
The Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) completed enrollment with 65 patients, with top-line results expected in September 2025. The Phase 3 CAPTIVATE trial in CIDP and Phase 2 MoMeNtum trial in MMN are progressing with results anticipated in 2H'26.
Financially, Dianthus reported $309.1 million in cash, providing runway into 2H'27. Q2 net loss was $31.6 million ($0.88 per share), with R&D expenses of $26.3 million and G&A expenses of $8.9 million.
Dianthus Therapeutics (NASDAQ:DNTH) ha comunicato i risultati finanziari del secondo trimestre 2025 e aggiornamenti aziendali, evidenziando notevoli progressi nei suoi programmi clinici. Il farmaco principale della societ脿, claseprubart (DNTH103), sta avanzando in diversi studi:
Lo studio di Fase 2 MaGic sulla Miastenia Gravis generalizzata (gMG) ha completato il reclutamento con 65 pazienti, con risultati preliminari attesi per settembre 2025. Lo studio di Fase 3 CAPTIVATE sulla CIDP e lo studio di Fase 2 MoMeNtum sulla MMN stanno procedendo con risultati previsti nella seconda met脿 del 2026.
Dal punto di vista finanziario, Dianthus ha riportato una liquidit脿 di 309,1 milioni di dollari, garantendo risorse fino alla seconda met脿 del 2027. La perdita netta del secondo trimestre 猫 stata di 31,6 milioni di dollari (0,88 dollari per azione), con spese per ricerca e sviluppo pari a 26,3 milioni di dollari e spese generali e amministrative di 8,9 milioni di dollari.
Dianthus Therapeutics (NASDAQ:DNTH) inform贸 los resultados financieros del segundo trimestre de 2025 y actualizaciones comerciales, destacando avances significativos en sus programas cl铆nicos. El principal candidato a medicamento de la compa帽铆a, claseprubart (DNTH103), avanza en m煤ltiples ensayos:
El ensayo de Fase 2 MaGic en Miastenia Gravis generalizada (gMG) complet贸 la inscripci贸n con 65 pacientes, con resultados preliminares esperados para septiembre de 2025. El ensayo de Fase 3 CAPTIVATE en CIDP y el ensayo de Fase 2 MoMeNtum en MMN est谩n en progreso, con resultados anticipados para la segunda mitad de 2026.
En cuanto a lo financiero, Dianthus report贸 309,1 millones de d贸lares en efectivo, proporcionando recursos hasta la segunda mitad de 2027. La p茅rdida neta del segundo trimestre fue de 31,6 millones de d贸lares (0,88 d贸lares por acci贸n), con gastos en I+D de 26,3 millones de d贸lares y gastos administrativos y generales de 8,9 millones de d贸lares.
Dianthus Therapeutics (NASDAQ:DNTH)電� 2025雲� 2攵勱赴 鞛 瓴瓣臣 氚� 靷梾 鞐呺嵃鞚错姼毳� 氚滍憸頃橂┌ 鞛勳儊 頂勲攴鸽灗鞐愳劀 欷戩殧頃� 歆勳爠鞚� 臧曥“頄堨姷雼堧嫟. 須岇偓鞚� 欤检殧 鞎诫 頉勲炒鞚� claseprubart (DNTH103)電� 鞐煬 鞛勳儊鞁滍棙鞐愳劀 歆勴枆 欷戩瀰雼堧嫟:
鞚茧皹頇� 欷戩攴茧霠レ(gMG)鞚� 雽�靸侅溂搿� 頃� 2靸� MaGic 鞁滍棙鞚� 65氇呾潣 頇橃瀽 霌彪鞚� 鞕勲頄堨溂氅�, 欤检殧 瓴瓣臣電� 2025雲� 9鞗旍棎 氚滍憸霅� 鞓堨爼鞛呺媹雼�. CIDP 雽�靸� 3靸� CAPTIVATE 鞁滍棙瓿� MMN 雽�靸� 2靸� MoMeNtum 鞁滍棙霃� 歆勴枆 欷戩澊氅�, 瓴瓣臣電� 2026雲� 頃橂皹旮办棎 鞓堨儊霅╇媹雼�.
鞛鞝侅溂搿� Dianthus電� 3鞏� 909毵� 雼煬鞚� 順勱笀鞚� 氤挫湢頃橁碃 鞛堨柎 2027雲� 頃橂皹旮瓣箤歆� 鞖挫榿 鞛愱笀鞚� 頇曤炒頄堨姷雼堧嫟. 2攵勱赴 靾滌啇鞁れ潃 3,160毵� 雼煬 (欤茧嫻 0.88雼煬)鞚挫棃鞙茧┌, 鞐瓣惮臧滊皽牍勲姅 2,630毵� 雼煬, 鞚茧皹甏�毽箘電� 890毵� 雼煬鞓赌鞀惦媹雼�.
Dianthus Therapeutics (NASDAQ:DNTH) a publi茅 ses r茅sultats financiers du deuxi猫me trimestre 2025 ainsi que des mises 脿 jour sur ses activit茅s, mettant en avant des progr猫s significatifs dans ses programmes cliniques. Le principal candidat-m茅dicament de la soci茅t茅, claseprubart (DNTH103), progresse dans plusieurs essais :
L'essai de phase 2 MaGic dans la myasth茅nie grave g茅n茅ralis茅e (gMG) a termin茅 son recrutement avec 65 patients, les r茅sultats principaux sont attendus pour septembre 2025. L'essai de phase 3 CAPTIVATE dans la CIDP et l'essai de phase 2 MoMeNtum dans la MMN avancent, avec des r茅sultats pr茅vus pour le second semestre 2026.
Sur le plan financier, Dianthus a d茅clar茅 disposer de 309,1 millions de dollars en liquidit茅s, assurant un financement jusqu'脿 la seconde moiti茅 de 2027. La perte nette du deuxi猫me trimestre s'茅l猫ve 脿 31,6 millions de dollars (0,88 dollar par action), avec des d茅penses de R&D de 26,3 millions de dollars et des frais g茅n茅raux et administratifs de 8,9 millions de dollars.
Dianthus Therapeutics (NASDAQ:DNTH) ver枚ffentlichte die Finanzergebnisse f眉r das zweite Quartal 2025 und Unternehmensupdates und hob bedeutende Fortschritte in seinen klinischen Programmen hervor. Der f眉hrende Wirkstoffkandidat des Unternehmens, claseprubart (DNTH103), befindet sich in mehreren Studien:
Die Phase-2-Studie MaGic bei generalisierter Myasthenia Gravis (gMG) hat die Einschreibung mit 65 Patienten abgeschlossen, die Hauptergebnisse werden f眉r September 2025 erwartet. Die Phase-3-Studie CAPTIVATE bei CIDP und die Phase-2-Studie MoMeNtum bei MMN schreiten voran, Ergebnisse werden f眉r das zweite Halbjahr 2026 erwartet.
Finanziell meldete Dianthus 309,1 Millionen US-Dollar an liquiden Mitteln, was einen finanziellen Spielraum bis zur zweiten H盲lfte 2027 bietet. Der Nettoverlust im zweiten Quartal betrug 31,6 Millionen US-Dollar (0,88 US-Dollar pro Aktie), mit F&E-Ausgaben von 26,3 Millionen US-Dollar und Verwaltungs- und Gemeinkosten von 8,9 Millionen US-Dollar.
- Strong cash position of $309.1 million providing extended runway into 2H'27
- Phase 2 MaGic trial exceeded enrollment target with 65 patients vs. 60 planned
- Multiple potential catalysts through 2026 across three clinical programs
- Significant market opportunity in gMG with only 10% of AChR+ patients currently on biologics
- Increased net loss to $31.6 million in Q2 2025 from $17.6 million in Q2 2024
- Higher R&D expenses of $26.3 million, up from $18.1 million year-over-year
- Increased G&A expenses to $8.9 million from $6.0 million year-over-year
Insights
Dianthus reports solid cash position of $309.1M with multiple near-term catalysts for claseprubart, supporting runway into 2H'27.
Dianthus Therapeutics is positioning itself for a critical inflection point with the upcoming readout of its Phase 2 MaGic trial for claseprubart in generalized Myasthenia Gravis (gMG) expected in September 2025. This represents the first of three potential catalysts for their neuromuscular franchise by the end of 2026, setting up a cascade of value-driving events.
The company's financial position remains strong with
The quarterly burn rate has increased with R&D expenses of
Market research conducted by Dianthus suggests significant untapped potential in the gMG market, with only
Beyond gMG, Dianthus maintains momentum with the ongoing Phase 3 CAPTIVATE trial in CIDP (interim analysis expected 2H'26) and Phase 2 MoMeNtum trial in MMN (results expected 2H'26). The synchronized timing of these catalysts creates a concentrated period of potential value creation in late 2026, though this also concentrates risk if results disappoint.
Claseprubart's three-pronged neuromuscular disease approach targets complementary indications with significant unmet needs, with initial gMG data imminent.
Dianthus's classical pathway inhibitor claseprubart (formerly DNTH103) represents a mechanistically differentiated approach in the complement inhibitor landscape. By selectively targeting only the active form of the C1s protein, the therapy aims to provide better safety while maintaining efficacy in autoantibody-mediated neurological disorders.
The company has strategically selected three complementary neuromuscular indications鈥攇MG, CIDP, and MMN鈥攖hat share pathophysiological mechanisms involving autoantibody-mediated complement activation. This creates potential synergies in development and eventual commercialization.
For the gMG program, the Phase 2 MaGic trial's September readout will be particularly important for validating the selective C1s inhibition approach. The trial exceeded its enrollment target (65 vs. 60 planned patients), potentially providing more robust statistical power. The focus on AChR+ patients鈥攚ho represent approximately
The CIDP program employs an efficient trial design with a randomized withdrawal Phase 3 study (CAPTIVATE), which has become the standard approach for this indication. The planned interim responder analysis in 2H'26 could provide an early efficacy signal. Notably, the company believes this single pivotal trial could support BLA filing, potentially accelerating time to market.
For MMN, a rare condition with limited treatment options primarily centered around IVIg, the Phase 2 MoMeNtum trial represents an opportunity to address a high-unmet need indication. This indication has fewer competitive programs in development compared to gMG and CIDP.
Claseprubart's subcutaneous administration with dosing as infrequently as once every two weeks could offer significant convenience advantages over current therapies, particularly for conditions like CIDP and MMN where current standard treatments often require frequent intravenous infusions.
Phase 2 MaGic trial of claseprubart (DNTH103) in generalized Myasthenia Gravis (gMG) top-line results anticipated in September 2025; the first of three catalysts for the claseprubart neuromuscular franchise by YE鈥�26
Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) ongoing; interim responder analysis anticipated in 2H鈥�26
Phase 2 MoMeNtum trial of claseprubart in Multifocal Motor Neuropathy (MMN) ongoing;
top-line results anticipated in 2H鈥�26
NEW YORK and WALTHAM, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the second quarter ending June 30, 2025, and provided an update on recent business achievements.
鈥淲e look forward to reporting top-line Phase 2 results from our MaGic trial with claseprubart in gMG in September. We believe the听multibillion-dollar gMG market has significant potential to expand, as only approximately
Claseprubart (DNTH103) Clinical Development
Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. Claseprubart is designed to enable a more convenient, subcutaneous, self-administered injection dosed as infrequently as once every two weeks. Claseprubart has the potential to be a best-in-class pipeline-in-a-product across a range of autoimmune disorders with high unmet need.
Generalized Myasthenia Gravis (gMG)
- Top-line Phase 2 MaGic gMG trial results anticipated in September: The is a global, randomized, double-blind, placebo-controlled Phase 2 trial in patients with gMG who are acetylcholine receptor (AChR) antibody positive. As previously announced in May, with 65 patients, exceeding the target of 60.
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Phase 3 CAPTIVATE CIDP trial ongoing: The is a single, global, two-part, randomized withdrawal Phase 3 trial in patients with CIDP, and it remains on track for an interim responder analysis in 2H鈥�26. The Company believes this single pivotal trial will support a BLA filing in adult patients with CIDP.
Multifocal Motor Neuropathy (MMN)
- Phase 2 MoMeNtum MMN trial ongoing: The is a global, randomized, double-blind, placebo-controlled Phase 2 trial in patients with MMN, and it remains on track to report top-line results in 2H鈥�26.
Corporate Updates
- The International Nonproprietary Name (INN) has been finalized and DNTH103, a potentially best-in-class investigational classical pathway inhibitor, is now called claseprubart.
- On May 22, 2025,听Simon Read, Ph.D.,. Dr. Read is a serial entrepreneur with more than 30 years of biopharmaceutical experience. He served as CEO and Founder of Mariana Oncology until its acquisition by Novartis in 2024 and CSO of Ra Pharma until its acquisition by UCB in 2020.
Second-Quarter 2025 Financial Results
- Cash Position -
$309.1 million of cash, cash equivalents and investments as of June 30, 2025 is projected to provide runway into the second half of 2027. - R&D Expenses - Research and development (R&D) expenses for the quarter ended June 30, 2025 were
$26.3 million , inclusive of$2.5 million of stock-based compensation, compared to$18.1 million for the quarter ended June 30, 2024, which included$1.4 million of stock-based compensation. This increase in R&D expenses was primarily driven by higher clinical costs, chemistry, manufacturing and controls (CMC) costs, and increased headcount to support claseprubart Phase 2 and Phase 3 development. - G&A Expenses - General and administrative (G&A) expenses for the quarter ended June 30, 2025 totaled
$8.9 million , inclusive of stock-based compensation of$3.2 million , compared to$6.0 million for the quarter ended June 30, 2024, which included$1.8 million of stock-based compensation. This increase in G&A expenses was primarily due to increased headcount. - Net Loss - Net loss for the quarter ended June 30, 2025 was
$31.6 million or$0.88 per share (basic and diluted) compared to$17.6 million or$0.51 per share (basic and diluted) for the quarter ended June 30, 2024. - Additional Information - For additional information on the Company鈥檚 financial results for the quarter ended June 30, 2025, please refer to the Form 10-Q filed with the SEC.
About Claseprubart
Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. Claseprubart is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, self-administered injection dosed as infrequently as once every two weeks. Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways. As the classical pathway plays a significant role in disease pathology, claseprubart has the potential to be a best-in-class pipeline-in-a-product across a range of autoimmune disorders with high unmet need. Dianthus is building a neuromuscular franchise with claseprubart and anticipates reporting top-line data from the Phase 2 MaGic trial in generalized Myasthenia Gravis in September 2025, the interim responder analysis of the Phase 3 CAPTIVATE trial in Chronic Inflammatory Demyelinating Polyneuropathy in 2H鈥�26, and top-line data from the Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy in 2H鈥�26.
Claseprubart is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.
About Dianthus Therapeutics
Dianthus Therapeutics is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who are leading the development of next-generation antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
To learn more, please visit and follow us on .听
Cautionary Statement Regarding Forward-Looking Statements
Certain statements in this press release, other than purely historical information, may constitute 鈥渇orward-looking statements鈥� within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995, express or implied statements regarding future plans and prospects, including statements regarding the expectations or plans for discovery, preclinical studies, clinical trials and research and development programs, in particular with respect to claseprubart, and any developments or results in connection therewith, including the target product profile and administration of claseprubart; the anticipated timing of the initiation and results from those studies and trials; expectations regarding the time period over which the Company鈥檚 capital resources are expected to be sufficient to fund its anticipated operations; and expectations regarding the market and potential opportunities for complement therapies, in particular with respect to claseprubart. Claseprubart is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide. The words 鈥渙pportunity,鈥� 鈥減otential,鈥� 鈥渕ilestones,鈥� 鈥渞unway,鈥� 鈥渨ill,鈥� 鈥渁nticipate,鈥� 鈥渁chieve,鈥� 鈥渘ear-term,鈥� 鈥渃atalysts,鈥� 鈥減ursue,鈥� 鈥減ipeline,鈥� 鈥渂elieve,鈥� 鈥渃ontinue,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥減lan,鈥� 鈥減ossible,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渟hould,鈥� 鈥渟trive,鈥� 鈥渨ould,鈥� 鈥渁im,鈥� 鈥渢arget,鈥� 鈥渃ommit,鈥� and similar expressions (including the negatives of these terms or variations of them) generally identify forward-looking statements, but the absence of these words does not mean that statement is not forward looking.
Actual results could differ materially from those included in the forward-looking statements due to various factors, risks and uncertainties, including, but not limited to, that preclinical testing of claseprubart and data from clinical trials may not be predictive of the results or success of ongoing or later clinical trials, that the development of claseprubart or the Company's other compounds may take longer and/or cost more than planned, that the Company may be unable to successfully complete the clinical development of the Company鈥檚 compounds, that the Company may be delayed in initiating, enrolling or completing its planned clinical trials, and that the Company's compounds may not receive regulatory approval or become commercially successful products. These and other risks and uncertainties are identified under the heading "Risk Factors" included in the Company鈥檚 Annual Report on Form 10-K for the period ended December 31, 2024, and other filings that the Company has made and may make with the SEC in the future. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved.
The forward-looking statements in this press release speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Dianthus undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Contact
Jennifer Davis Ruff
Dianthus Therapeutics
| DIANTHUS THERAPEUTICS, INC. Condensed Consolidated Balance Sheets (in thousands, except share and per share data) (unaudited) | |||||||
| 听 | |||||||
| 听 | June 30, 2025 | 听 | 听 | December听31, 2024 | 听 | ||
| Assets | 听 | 听 | 听 | 听 | 听 | ||
| Current assets: | 听 | 听 | 听 | 听 | 听 | ||
| Cash and cash equivalents | $ | 13,237 | 听 | 听 | $ | 22,792 | 听 |
| Short-term investments | 听 | 244,152 | 听 | 听 | 听 | 252,449 | 听 |
| Receivable from former related party | 听 | 鈥� | 听 | 听 | 听 | 807 | 听 |
| Accounts receivable, net | 听 | 39 | 听 | 听 | 听 | 鈥� | 听 |
| Prepaid expenses and other current assets | 听 | 6,177 | 听 | 听 | 听 | 4,856 | 听 |
| Total current assets | 听 | 263,605 | 听 | 听 | 听 | 280,904 | 听 |
| Long-term investments | 听 | 51,705 | 听 | 听 | 听 | 81,728 | 听 |
| Property and equipment, net | 听 | 207 | 听 | 听 | 听 | 194 | 听 |
| Right-of-use operating lease assets | 听 | 1,378 | 听 | 听 | 听 | 1,553 | 听 |
| Other assets and restricted cash | 听 | 9,181 | 听 | 听 | 听 | 9,629 | 听 |
| Total assets | $ | 326,076 | 听 | 听 | $ | 374,008 | 听 |
| Liabilities and Stockholders鈥� Equity | 听 | 听 | 听 | 听 | 听 | ||
| Current liabilities: | 听 | 听 | 听 | 听 | 听 | ||
| Accounts payable | $ | 5,404 | 听 | 听 | $ | 4,579 | 听 |
| Accrued expenses | 听 | 13,999 | 听 | 听 | 听 | 13,074 | 听 |
| Current portion of deferred revenue | 听 | 479 | 听 | 听 | 听 | 479 | 听 |
| Current portion of operating lease liabilities | 听 | 211 | 听 | 听 | 听 | 320 | 听 |
| Total current liabilities | 听 | 20,093 | 听 | 听 | 听 | 18,452 | 听 |
| Deferred revenue | 听 | 1,785 | 听 | 听 | 听 | 1,908 | 听 |
| Long-term operating lease liabilities | 听 | 1,119 | 听 | 听 | 听 | 1,171 | 听 |
| Total liabilities | 听 | 22,997 | 听 | 听 | 听 | 21,531 | 听 |
| Commitments and contingencies | 听 | 听 | 听 | 听 | 听 | ||
| Stockholders鈥� equity: | 听 | 听 | 听 | 听 | 听 | ||
| Preferred stock | 听 | 鈥� | 听 | 听 | 听 | 鈥� | 听 |
| Common stock | 听 | 32 | 听 | 听 | 听 | 31 | 听 |
| Additional paid-in capital | 听 | 538,481 | 听 | 听 | 听 | 526,732 | 听 |
| Accumulated deficit | 听 | (235,532 | ) | 听 | 听 | (174,392 | ) |
| Accumulated other comprehensive income | 听 | 98 | 听 | 听 | 听 | 106 | 听 |
| Total stockholders鈥� equity | 听 | 303,079 | 听 | 听 | 听 | 352,477 | 听 |
| Total liabilities and stockholders鈥� equity | $ | 326,076 | 听 | 听 | $ | 374,008 | 听 |
| DIANTHUS THERAPEUTICS, INC. Condensed Consolidated Statements of Operations and Comprehensive Loss (in thousands, except share and per share data) (unaudited) | ||||||||||||||||
| 听 | ||||||||||||||||
| 听 | Three Months Ended June听30, | 听 | 听 | Six Months Ended June听30, | 听 | |||||||||||
| 听 | 2025 | 听 | 听 | 2024 | 听 | 听 | 2025 | 听 | 听 | 2024 | 听 | |||||
| Revenues: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | |||||
| License revenue 鈥� former related party | $ | 鈥� | 听 | 听 | $ | 1,863 | 听 | 听 | $ | 鈥� | 听 | 听 | $ | 2,737 | 听 | |
| License revenue | 听 | 193 | 听 | 听 | 听 | 鈥� | 听 | 听 | 听 | 1,356 | 听 | 听 | 听 | 鈥� | 听 | |
| Total revenues | 听 | 193 | 听 | 听 | 听 | 1,863 | 听 | 听 | 听 | 1,356 | 听 | 听 | 听 | 2,737 | 听 | |
| Operating expenses: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | |||||
| Research and development | 听 | 26,251 | 听 | 听 | 听 | 18,070 | 听 | 听 | 听 | 53,254 | 听 | 听 | 听 | 31,148 | 听 | |
| General and administrative | 听 | 8,869 | 听 | 听 | 听 | 5,997 | 听 | 听 | 听 | 16,206 | 听 | 听 | 听 | 11,637 | 听 | |
| Total operating expenses | 听 | 35,120 | 听 | 听 | 听 | 24,067 | 听 | 听 | 听 | 69,460 | 听 | 听 | 听 | 42,785 | 听 | |
| Loss from operations | 听 | (34,927 | ) | 听 | 听 | (22,204 | ) | 听 | 听 | (68,104 | ) | 听 | 听 | (40,048 | ) | |
| Other income/(expense): | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | |||||
| Interest and investment income | 听 | 3,403 | 听 | 听 | 听 | 4,708 | 听 | 听 | 听 | 7,194 | 听 | 听 | 听 | 8,930 | 听 | |
| Gain on investment in former related party | 听 | 32 | 听 | 听 | 听 | 鈥� | 听 | 听 | 听 | 27 | 听 | 听 | 听 | 鈥� | 听 | |
| Loss on currency exchange, net | 听 | (30 | ) | 听 | 听 | (31 | ) | 听 | 听 | (52 | ) | 听 | 听 | (43 | ) | |
| Other expense | 听 | (107 | ) | 听 | 听 | (80 | ) | 听 | 听 | (205 | ) | 听 | 听 | (194 | ) | |
| Total other income | 听 | 3,298 | 听 | 听 | 听 | 4,597 | 听 | 听 | 听 | 6,964 | 听 | 听 | 听 | 8,693 | 听 | |
| Net loss | $ | (31,629 | ) | 听 | $ | (17,607 | ) | 听 | $ | (61,140 | ) | 听 | $ | (31,355 | ) | |
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.88 | ) | 听 | $ | (0.51 | ) | 听 | $ | (1.71 | ) | 听 | $ | (0.99 | ) | |
| Weighted-average number of shares of common stock outstanding including shares issuable under equity classified pre-funded warrants, used in computing net loss per share of common stock, basic and diluted | 听 | 35,822,308 | 听 | 听 | 听 | 34,227,038 | 听 | 听 | 听 | 35,806,591 | 听 | 听 | 听 | 31,794,881 | 听 | |
| Comprehensive loss: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | |||||
| Net loss | $ | (31,629 | ) | 听 | $ | (17,607 | ) | 听 | $ | (61,140 | ) | 听 | $ | (31,355 | ) | |
| Other comprehensive loss: | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | 听 | |||||
| Unrealized loss on marketable securities | 听 | (172 | ) | 听 | 听 | (10 | ) | 听 | 听 | (8 | ) | 听 | 听 | (84 | ) | |
| Total other comprehensive loss | 听 | (172 | ) | 听 | 听 | (10 | ) | 听 | 听 | (8 | ) | 听 | 听 | (84 | ) | |
| Total comprehensive loss | $ | (31,801 | ) | 听 | $ | (17,617 | ) | 听 | $ | (61,148 | ) | 听 | $ | (31,439 | ) | |
FAQ
What are the key clinical trial milestones for Dianthus Therapeutics (DNTH) in 2025-2026?
How much cash does Dianthus Therapeutics (DNTH) have and what is their runway?
What was Dianthus Therapeutics' (DNTH) Q2 2025 financial performance?
What is claseprubart (DNTH103) and what are its potential advantages?
What is the market opportunity for Dianthus Therapeutics (DNTH) in gMG?
